The Trial Ed Pack offers a clinically validated, multi-agent approach to managing erectile dysfunction, providing physicians and informed patients with a flexible, evidence-based therapeutic option. This curated pack includes small quantities of leading PDE5 inhibitors, allowing for individualized titration under medical supervision while minimizing initial investment and potential side effect exposure. Designed for diagnostic and therapeutic versatility, it supports both first-line treatment initiation and comparative efficacy assessment in real-world settings.

Features

• Contains 2 tablets of Sildenafil 100mg (Viagra® equivalent)
• Contains 2 tablets of Tadalafil 20mg (Cialis® equivalent)
• Contains 2 tablets of Vardenafil 20mg (Levitra® equivalent)
• Blister-packed with clear dosage and agent identification
• Includes manufacturer-provided prescribing information for each agent
• Temperature-stable packaging compliant with pharmaceutical transport standards

Benefits

• Enables personalized therapy selection through direct comparison of drug onset, duration, and side effect profiles
• Reduces initial treatment costs by avoiding full prescription commitments to potentially unsuitable medications
• Provides immediate therapeutic options for patients requiring rapid intervention while determining optimal long-term management
• Supports evidence-based prescribing decisions through controlled patient experience data collection
• Minimizes medication waste through appropriate sample sizing
• Facilitates patient-physician dialogue about treatment preferences and tolerability

Common use

The Trial Ed Pack is primarily utilized in urological and primary care settings for patients presenting with newly diagnosed erectile dysfunction of various etiologies. It serves as both a diagnostic tool and initial treatment strategy, particularly valuable for patients who have failed monotherapy or present with complex comorbidities affecting drug metabolism. The pack is also employed in cases where cost sensitivity or medication apprehension requires demonstration of efficacy before committing to a full prescription.

Dosage and direction

Each medication within the pack follows distinct dosing protocols:

Sildenafil: Administer 1 tablet (100mg) approximately 30-60 minutes prior to anticipated sexual activity. Maximum dosing frequency: once daily. Effectiveness may be reduced with high-fat meals.

Tadalafil: Administer 1 tablet (20mg) at least 30 minutes prior to sexual activity. Effective for up to 36 hours. May be taken without regard to meals.

Vardenafil: Administer 1 tablet (20mg) 25-60 minutes before sexual activity. Avoid high-fat meals concurrent with administration. Maximum dosing frequency: once daily.

All agents require sexual stimulation for efficacy. Initiate with lowest effective dose based on individual response and tolerability.

Precautions

Cardiovascular assessment is mandatory before prescribing. Sexual activity presents cardiac risk, particularly in patients with pre-existing cardiovascular disease. PDE5 inhibitors may cause hypotension. Avoid use in patients with anatomical penile deformities, sickle cell anemia, multiple myeloma, or leukemia due to potential priapism risk. Monitor visual changes as non-arteritic anterior ischemic optic neuropathy (NAION) has been reported. Sudden hearing loss has been reported rarely. Use caution in patients with bleeding disorders or active peptic ulceration.

Contraindications

Concomitant use with organic nitrates in any form. Concomitant use with guanylate cyclase stimulators (riociguat). Hypersensitivity to any component of the formulations. Severe hepatic impairment (Child-Pugh Class C). Severe hypotension (<90/50 mmHg). Recent stroke or myocardial infarction (within 6 months). Unstable angina or life-threatening arrhythmias.

Possible side effects

Common (≥2%): headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, dizziness, visual disturbances (including cyanopsia and photophobia). Less common: hypotension, palpitations, priapism, hearing changes, retinal vascular occlusion. Rare: serious cardiovascular events, seizure, anaphylaxis.

Drug interaction

Contraindicated with nitrates and nitric oxide donors. Potent CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) may significantly increase concentrations—dose adjustment required. Alpha-blockers may potentiate hypotensive effects—separate administration by 4 hours. Grapefruit juice may increase bioavailability. Antacids may reduce absorption of sildenafil. Interactions with antihypertensives, protease inhibitors, and other CYP3A4 substrates possible.

Missed dose

Not applicable to as-needed dosing regimen. If a dose is forgotten and sexual activity is anticipated, take medication at the appropriate pre-coital interval. Do not double dose within 24 hours.

Overdose

Symptoms may include severe headache, flushing, dizziness, hypotension, syncope, and prolonged erection. Supportive measures include Trendelenburg positioning and IV fluids for hypotension. Priapism lasting more than 4 hours requires immediate urological intervention to prevent permanent tissue damage. Dialysis not effective due to high protein binding.

Storage

Store at 20-25°C (68-77°F). Excursions permitted between 15-30°C (59-86°F). Keep in original blister packaging. Protect from light and moisture. Keep out of reach of children. Do not use after expiration date printed on packaging.

Disclaimer

This medication requires prescription and medical supervision. Not for use by women or children. The Trial Ed Pack is intended for medical professional use in therapeutic decision-making. Individual results may vary. This product does not protect against sexually transmitted diseases. Patients should report any erection lasting more than 4 hours immediately.

Reviews

“Excellent tool for determining optimal PDE5 inhibitor therapy. The comparative approach saved my patient from weeks of ineffective monotherapy trials.” — Dr. Evan R., Urologist

“Allowed me to find the right medication with minimal side effects. The small quantity reduced my anxiety about committing to a full prescription.” — Patient, 52

“Practical solution for patients with variable sexual frequency patterns. The inclusion of both short and long-acting agents provides valuable flexibility.” — Dr. Lisa M., Internal Medicine